ODI Pharma AB: Publication of interim report for the third quarter 2020/2021
ODI Pharma AB (“ODI” or “the Company”) hereby publishes its interim report concerning the period July 2020 – March 2021. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Third quarter (2021-01-01 – 2021-03-31) The Group's net sales amounted to SEK 0 (SEK 1,567). The Group's loss after financial items amounted to SEK -41,280 (SEK -1,662,333). Result per share amounted to SEK -0.0031 (SEK -0.11).* The solidity as of 2021-03-31 was 99.63% (93.51%).** Nine months (2020-07-01 –